Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group
| Autor: | Carsten Rose, B. Kristensen, Jens O. Andersen, Bent Ejlertsen, H.T. Mouridsen, Inger Højris, K Møholt, Steinbjørn Hansen, Mogens Kjaer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2003 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment Breast Neoplasms Pilot Projects Vinblastine Vinorelbine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Aged Epirubicin Chemotherapy Dose-Response Relationship Drug business.industry Cancer General Medicine Middle Aged medicine.disease Metastatic breast cancer Acute toxicity Treatment Outcome Tolerability Feasibility Studies Female Surgery business medicine.drug |
| Zdroj: | Ejlertsen, B, Højris, I, Hansen, S, Møholt, K, Kristensen, B, Mouridsen, H T, Andersen, J, Rose, C & Kjær, M 2003, ' Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group ', Breast, vol. 12, no. 1, pp. 42-50 . https://doi.org/10.1016/S0960-9776(02)00180-7 Ejlertsen, B, Hojris, I, Hansen, S, Moholt, K, Kristensen, B, Mouridsen, H T, Andersen, J, Rose, C & Kjaer, M 2003, ' Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer : a pilot study performed by the Danish Breast Cancer Cooperative Group ', Breast, vol. 12, no. 1, pp. 42-50 . https://doi.org/10.1016/S0960-9776(02)00180-7 |
| DOI: | 10.1016/S0960-9776(02)00180-7 |
| Popis: | This pilot study investigated the tolerability and efficacy of increasing doses of epirubicin and vinorelbine as first-line chemotherapy for metastatic breast cancer. Acute toxicity was manageable at all dose levels for combinations of epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8 repeated every 3 weeks. Myelotoxicity was the most frequent toxic event, with a significant increase in grade 4 leukopenia from 0% at dose level 1 (60+15 mg/m2) to 26% at dose level 6 (90+25 mg/m2). Signs of acute or chronic cardiotoxicity grades 2-4 were seen in 15% of the patients and included arrhythmia and decreased function. No significant association was established between dose and nonhematological toxicity. Objective responses were observed in 49 of the 99 evaluable patients (49.5%, 95% CI 39.9-59.2), 18 being complete and 31 partial responses. Responses were observed at all six dose levels. In conclusion, acute toxicity was manageable at all dose levels for combinations of epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8. In the treatment of advanced breast cancer, improvement of the antitumor efficacy by the addition of vinorelbine to epirubicin remains to be demonstrated in a randomized phase III trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|